{"id":"W4305015938","doi":"10.1038/s41591-022-02015-7","title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Irving Medical Center, Columbia University; National Cancer Institute; University of Toronto; Cancer Center, University of Colorado; Weill Cornell Medical College; University of Oklahoma; Centro de Investigación Biomédica en Red de Cáncer; Stephenson Cancer Center; Vanderbilt University Medical Center; Cedars-Sinai Medical Center; University of Pittsburgh; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center; Vanderbilt University","keywords":"Medicine; Clinical endpoint; Melanoma; Internal medicine; Rash; Adverse effect; Clinical trial; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Survival rate; Surrogate endpoint; Progression-free survival; Surgery; Gastroenterology; Overall survival; Cancer research","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001217677,0.0002217132,0.0007489622,0.0003323244,0.00008650075,0.000003148637,0.00008564376,0.0001431753,0.0002344393],"category_scores_gemma":[0.0008681049,0.0001452554,0.00005925024,0.0005574194,0.0001523491,0.00003035934,0.0000720199,0.0009603791,0.00000490529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001501894,"about_ca_system_score_gemma":0.0001641892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003396082,"about_ca_topic_score_gemma":0.0000280235,"domain_scores_codex":[0.9974435,0.0007938913,0.0004702081,0.0004711391,0.0005369505,0.0002843068],"domain_scores_gemma":[0.9988875,0.0003222641,0.000110926,0.0003086895,0.00007183245,0.0002987655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6351681,0.005822132,0.3394973,0.00003409376,0.0005310339,0.00617222,0.0006648368,0.000001715373,0.000259262,0.00003349051,0.001268208,0.01054769],"study_design_scores_gemma":[0.6887861,0.09797855,0.1959719,0.0001583793,0.001411409,0.0001716146,0.0002232294,0.00002272716,0.0001228843,0.00004681915,0.01488372,0.0002226311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913066,0.00115328,0.000009916584,0.004263489,0.0002578787,0.002758989,0.00002592764,0.00003186888,0.0001920395],"genre_scores_gemma":[0.9954076,0.0000107965,0.0004697595,0.00331276,0.00007192144,0.0002184822,0.0002088509,0.00002743678,0.0002724013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1435253,"threshold_uncertainty_score":0.5923343,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0131082228485558,"score_gpt":0.3671599209829994,"score_spread":0.3540516981344436,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}